Modern approaches to accelerate discovery of new antischistosomal drugs

Expert Opinion on Drug Discovery

Volumn 11, Issue 6, 2016, Pages 557-567

  Neves, Bruno Junior ^a   Muratov, Eugene ^b   Machado, Renato Beilner ^a   Andrade, Carolina Horta ^a   Cravo, Pedro Vitor Lemos ^a,c  

^a FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

Author keywords

automated assays; computer aided molecular design; data quality; drug discovery; perspectives; Schistosomiasis; virtual screening

Indexed keywords

ANTISCHISTOSOMAL AGENT; LIGAND; PROTEIN;

ACCELERATION; DRUG SCREENING; DRUG TARGETING; FLUORESCENCE ANALYSIS; HUMAN; IMPEDANCE; ISOTHERM; LUMINESCENCE; MICROCALORIMETRY; MOLECULAR DOCKING; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTON TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; SCHISTOSOMA; TAUTOMER; ANIMAL; CHEMICAL DATABASE; COMPUTER AIDED DESIGN; DRUG DESIGN; DRUG DEVELOPMENT; DRUG RESISTANCE; PARASITOLOGY; PROCEDURES; SCHISTOSOMIASIS;

ANIMALS; COMPUTER-AIDED DESIGN; DATABASES, CHEMICAL; DRUG DESIGN; DRUG DISCOVERY; DRUG RESISTANCE; HUMANS; SCHISTOSOMIASIS; SCHISTOSOMICIDES;

EID: 84965047083     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1080/17460441.2016.1178230     Document Type: Review

References (100)

1. D.G.Colley, A.L.Bustinduy, W.E.Secor, et al. Human schistosomiasis. Lancet. 2014;383:2253–2264. doi:10.1016/S0140-6736(13)61612-8.•• Very concise and clear description of schistosomiasis.
2. World Health Organization. Schistosomiasis [Internet]; [cited 2016 Jan3] Available from: http://www.who.int/mediacentre/factsheets/fs115/en/
3. R.Gönnert, P.Andrews Praziquantel, a new board-spectrum antischistosomal agent. Z Parasitenkd. 1977;52:129–150. doi:10.1007/BF00389899.
4. M.Ismail, A.Metwally, A.Farghaly, et al. Characterization of isolates of Schistosoma mansoni from Egyptian villagers that tolerate high doses of praziquantel. Am J Trop Med Hyg. 1996;55:214–218.
5. P.G.Fallon, R.F.Sturrock, A.C.Niang, et al. Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni. Am J Trop Med Hyg. 1995;53:61–62.
6. W.Wang, L.Wang, Y.Liang. Susceptibility or resistance of praziquantel in human schistosomiasis: a review. Parasitol Res. 2012;111:1871–1877. doi:10.1007/s00436-012-2938-2.
7. C.R.Caffrey, W.E.Secor. Schistosomiasis: from drug deployment to drug development. Curr Opin Infect Dis. 2011;24:410–417. doi:10.1097/QCO.0b013e328349156f.
8. T.G.Geary, J.A.Sakanari, C.R.Caffrey. Anthelmintic drug discovery: into the future. J Parasitol. 2015;101:125–133. doi:10.1645/15-767.
9. B.Ramirez, Q.Bickle, F.Yousif, et al. Schistosomes: challenges in compound screening. Expert Opin Drug Discov. 2007;2:S53–S61. doi:10.1517/17460441.2.1.115.
10. J.Keiser. In vitro and in vivo trematode models for chemotherapeutic studies. Parasitology. 2010;137:589–603. doi:10.1017/S0031182009991739.
11. S.Nwaka, A.Hudson. Innovative lead discovery strategies for tropical diseases. Nat Rev Drug Discov. 2006;5:941–955. doi:10.1038/nrd2144.•• Overview of drug discovery for neglected tropical diseases.
12. M.Berriman, B.J.Haas, P.T.LoVerde, et al. The genome of the blood fluke Schistosoma mansoni. Nature. 2009;460:352–358. doi:10.1038/nature08160.
13. A.V.Protasio, I.J.Tsai, A.Babbage, et al. A systematically improved high quality genome and transcriptome of the human blood fluke Schistosoma mansoni. PLoS Negl Trop Dis. 2012;6:e1455. doi:10.1371/journal.pntd.0001455.
14. Y.Zhou, H.Zheng, Y.Chen, et al. The Schistosoma japonicum genome reveals features of host–parasite interplay. Nature. 2009;460:345–351. doi:10.1038/nature08140.
15. N.D.Young, A.R.Jex, B.Li, et al. Whole-genome sequence of Schistosoma haematobium. Nat Genet. 2012;44:221–225. doi:10.1038/ng.1065.•• Schistosome genomics data available to start drug discovery projects.
16. J.A.Frearson, I.T.Collie. HTS and hit finding in academia – from chemical genomics to drug discovery. Drug Discov Today. 2009;14:1150–1158. doi:10.1016/j.drudis.2009.09.004.
17. S.Rees. The promise of open innovation in drug discovery: an industry perspective. Future Med Chem. 2015;7:1835–1838. doi:10.4155/fmc.15.125.
18. J.L.Dahlin, M.A.Walters. The essential roles of chemistry in high-throughput screening triage. Future Med Chem. 2014;6:1265–1290. doi:10.4155/fmc.14.60.
19. A.Simeonov, A.Jadhav, A.A.Sayed, et al. Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade. PLoS Negl Trop Dis. 2008;2:e127. doi:10.1371/journal.pntd.0000127.
20. I.Kuhn, E.Kellenberger, F.Said-Hassane, et al. Identification by high-throughput screening of inhibitors of Schistosoma mansoni NAD(+) catabolizing enzyme. Bioorg Med Chem. 2010;18:7900–7910. doi:10.1016/j.bmc.2009.12.033.
21. A.N.Kuntz, E.Davioud-Charvet, A.A.Sayed, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007;4:e206. doi:10.1371/journal.pmed.0040206.
22. A.A.Sayed, A.Simeonov, C.J.Thomas, et al. Identification of oxadiazoles as new drug leads for the control of schistosomiasis. Nat Med. 2008;14:407–412. doi:10.1038/nm1737.
23. R.A.Paveley, Q.D.Bickle. Automated imaging and other developments in whole-organism anthelmintic screening. Parasite Immunol. 2013;35:302–313. doi:10.1111/pim.2013.35.issue-9pt10.
24. T.Manneck, O.Braissant, Y.Haggenmuller, et al. Isothermal microcalorimetry to study drugs against Schistosoma mansoni. J Clin Microbiol. 2011;49:1217–1225. doi:10.1128/JCM.02382-10.
25. M.J.Smout, A.C.Kotze, J.S.McCarthy, et al. A novel high throughput assay for anthelmintic drug screening and resistance diagnosis by real-time monitoring of parasite motility. PLoS Negl Trop Dis. 2010;4:e885. doi:10.1371/journal.pntd.0000885.
26. G.Rinaldi, A.Loukas, P.J.Brindley, et al. Viability of developmental stages of Schistosoma mansoni quantified with xCELLigence worm real-time motility assay (xWORM). Int J Parasitol Drugs Drug Resist. 2015;5:141–148. doi:10.1016/j.ijpddr.2015.07.002.
27. D.E.Asarnow, R.Singh. Segmenting the etiological agent of schistosomiasis for high-content screening. IEEE Trans Med Imaging. 2013;32:1007–1018. doi:10.1109/TMI.2013.2247412.
28. D.Asarnow, L.Rojo-Arreola, B.M.Suzuki, et al. The QDREC web server: determining dose-response characteristics of complex macroparasites in phenotypic drug screens. Bioinformatics. 2015;31:1515–1518. doi:10.1093/bioinformatics/btu831.
29. R.A.Paveley, N.R.Mansour, I.Hallyburton, et al. Whole organism high-content screening by label-free, image-based Bayesian classification for parasitic diseases. PLoS Negl Trop Dis. 2012;6:e1762. doi:10.1371/journal.pntd.0001762.
30. C.Marcellino, J.Gut, K.C.Lim, et al. WormAssay: a novel computer application for whole-plate motion-based screening of macroscopic parasites. PLoS Negl Trop Dis. 2012;6:e1494. doi:10.1371/journal.pntd.0001494.• A concise and clear description of three different HCS assays.
31. G.Panic, D.Flores, K.Ingram-Sieber, et al. Fluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays. Parasit Vectors. 2015;8:624. doi:10.1186/s13071-015-1233-3.
32. N.R.Mansour, Q.D.Bickle. Comparison of microscopy and Alamar blue reduction in a larval based assay for schistosome drug screening. PLoS Negl Trop Dis. 2010;4:e795. doi:10.1371/journal.pntd.0000795.
33. M.Marxer, K.Ingram, J.Keiser. Development of an in vitro drug screening assay using Schistosoma haematobium schistosomula. Parasit Vectors. 2012;5:165. doi:10.1186/1756-3305-5-123.
34. E.Peak, I.W.Chalmers, K.F.Hoffmann. Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect schistosoma viability. PLoS Negl Trop Dis. 2010;4:e759. doi:10.1371/journal.pntd.0000759.
35. S.Howe, D.Zöphel, H.Subbaraman, et al. Lactate as a novel quantitative measure of viability in Schistosoma mansoni drug sensitivity assays. Antimicrob Agents Chemother. 2015;59:1193–1199. doi:10.1128/AAC.03809-14.
36. C.Lalli, A.Guidi, N.Gennari, et al. Development and validation of a luminescence-based, medium-throughput assay for drug screening in Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9:e0003484. doi:10.1371/journal.pntd.0003484.• A concise and clear description of several fluorescence/luminescence-based assays.
37. C.Nantasenamat, V.Prachayasittikul. Maximizing computational tools for successful drug discovery. Expert Opin Drug Discov. 2015;10:321–329. doi:10.1517/17460441.2015.1016497.
38. Y.Wang, J.Xiao, T.O.Suzek, et al. PubChem’s BioAssay database. Nucleic Acids Res. 2012;40:D400–D412. doi:10.1093/nar/gkr1132.
39. T.Liu, Y.Lin, X.Wen, et al. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res. 2007;35:D198–D201. doi:10.1093/nar/gkl999.
40. A.Gaulton, L.J.Bellis, A.P.Bento, et al. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012;40:D1100–D1107. doi:10.1093/nar/gkr777.
41. D.Goldmann, F.Montanari, L.Richter, et al. Exploiting open data: a new era in pharmacoinformatics. Future Med Chem. 2014;6:503–514. doi:10.4155/fmc.14.13.• Importance of open data in drug discovery.
42. M.Karthikeyan, R.Vyas. Role of open source tools and resources in virtual screening for drug discovery. Comb Chem High Throughput Screen. 2015;18:528–543. doi:10.2174/1386207318666150703111911.
43. Y.Tanrikulu, B.Krüger, E.Proschak. The holistic integration of virtual screening in drug discovery. Drug Discov Today. 2013;18:358–364. doi:10.1016/j.drudis.2013.01.007.
44. S.Kar, K.Roy. How far can virtual screening take us in drug discovery? Expert Opin Drug Discov. 2013;8:245–261. doi:10.1517/17460441.2013.761204.
45. T.Zhu, S.Cao, P.-C.Su, et al. Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis. J Med Chem. 2013;56:6560–6572. doi:10.1021/jm301916b.
46. S.Kannan, J.Melesina, A.-T.Hauser, et al. Discovery of inhibitors of Schistosoma mansoni HDAC8 by combining homology modeling, virtual screening, and in vitro validation. J Chem Inf Model. 2014;54:3005–3019. doi:10.1021/ci5004653.
47. J.Liu, D.Dyer, J.Wang, et al. 3-oxoacyl-ACP reductase from Schistosoma japonicum: integrated in silico-in vitro strategy for discovering antischistosomal lead compounds. PLoS One. 2013;8:e64984. doi:10.1371/journal.pone.0064984.
48. J.Liu, D.H.Dyer, J.Cheng, et al. Aldose reductase from Schistosoma japonicum: crystallization and structure-based inhibitor screening for discovering antischistosomal lead compounds. Parasit Vectors. 2013;6:1–10. doi:10.1186/1756-3305-6-162.
49. M.P.Postigo, R.V.C.Guido, G.Oliva, et al. Discovery of new inhibitors of Schistosoma mansoni PNP by pharmacophore-based virtual screening. J Chem Inf Model. 2010;50:1693–1705. doi:10.1021/ci100128k.
50. + catabolizing enzyme. J Med Chem. 2015;58:3582–3592. doi:10.1021/acs.jmedchem.5b00203.
51. L.G.Ferreira, G.Oliva, A.D.Andricopulo. Target-based molecular modeling strategies for schistosomiasis drug discovery. Future Med Chem. 2015;7:753–764. doi:10.4155/fmc.15.21.
52. E.Lionta, G.Spyrou, D.K.Vassilatis, et al. Structure-based virtual screening for drug discovery: principles, applications and recent advances. Curr Top Med Chem. 2014;14:1923–1938. doi:10.2174/1568026614666140929124445.
53. P.W.Rose, A.Prlić, C.Bi, et al. The RCSB Protein Data Bank: views of structural biology for basic and applied research and education. Nucleic Acids Res. 2015;43:D345–D356. doi:10.1093/nar/gku1214.
54. L.Ferreira, R.dos Santos, G.Oliva, et al. Molecular docking and structure-based drug design strategies. Molecules. 2015;20:13384–13421. doi:10.3390/molecules200713384.
55. N.M.F.S.A.Cerqueira, D.Gesto, E.F.Oliveira, et al. Receptor-based virtual screening protocol for drug discovery. Arch Biochem Biophys. 2015;582:56–67. doi:10.1016/j.abb.2015.05.011.
56. S.Pirhadi, F.Shiri, J.B.Ghasemi. Methods and applications of structure based pharmacophores in drug discovery. Curr Top Med Chem. 2013;13:1036–1047. doi:10.2174/1568026611313090006.
57. F.Caporuscio, A.Tafi. Pharmacophore modelling: a forty year old approach and its modern synergies. Curr Med Chem. 2011;18:2543–2553. doi:10.2174/092986711795933669.
58. M.Njoroge, N.M.Njuguna, P.Mutai, et al. Recent approaches to chemical discovery and development against malaria and the neglected tropical diseases human african trypanosomiasis and schistosomiasis. Chem Rev. 2014;114:11138–11163. doi:10.1021/cr500098f.
59. B.J.Neves, R.C.Braga, J.C.B.Bezerra, et al. In silico repositioning-chemogenomics strategy identifies new drugs with potential activity against multiple life stages of Schistosoma mansoni. PLoS Negl Trop Dis. 2015;9:e3435. doi:10.1371/journal.pntd.0003435.•• Example of state-of-the-art strategy for drug repurposing.
60. P.Ripphausen, B.Nisius, J.Bajorath. State-of-the-art in ligand-based virtual screening. Drug Discov Today. 2011;16:372–376. doi:10.1016/j.drudis.2011.02.011.
61. I.Muegge, P.Mukherjee. An overview of molecular fingerprint similarity search in virtual screening. Expert Opin Drug Discov. 2015;11:1–12 doi:10.1517/17460441.2016.1117070.
62. A.Cereto-Massagué, M.J.Ojeda, C.Valls, et al. Molecular fingerprint similarity search in virtual screening. Methods. 2015;71:58–63. doi:10.1016/j.ymeth.2014.08.005.
63. A.Vuorinen, D.Schuster. Methods for generating and applying pharmacophore models as virtual screening filters and for bioactivity profiling. Methods. 2015;71:113–134. doi:10.1016/j.ymeth.2014.10.013.
64. D.R.Koes, C.J.Camacho. Shape-based virtual screening with volumetric aligned molecular shapes. J Comput Chem. 2014;35:1824–1834. doi:10.1002/jcc.v35.25.
65. S.Kortagere, M.D.Krasowski, S.Ekins. The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci. 2009;30:138–147. doi:10.1016/j.tips.2008.12.001.
66. L.Ghemtio, V.I.Perez-Nueno, V.Leroux, et al. Recent trends and applications in 3D virtual screening. Comb Chem High Throughput Screen. 2012;15:749–769. doi:10.2174/138620712803519707.
67. A.Cherkasov, E.N.Muratov, D.Fourches, et al. QSAR modeling: where have you been? Where are you going to? J Med Chem. 2014;57:4977–5010. doi:10.1021/jm401509e.• Perspectives of QSAR evolution.
68. L.Breiman. Random forests. Mach Learn. 2001;45:5–32. doi:10.1023/A:1010933404324.
69. V.Vapnik. The nature of statistical learning theory. 2nd ed. New York (NY): Springer; 2000. doi:10.1007/978-1-4757-3264-1.
70. E.N.Muratov, A.G.Artemenko, E.V.Varlamova, et al. Per aspera ad astra: application of Simplex QSAR approach in antiviral research. Future Med Chem. 2010;2:1205–1226. doi:10.4155/fmc.10.194.
71. F.Dubois, S.Caby, F.Oger, et al. Histone deacetylase inhibitors induce apoptosis, histone hyperacetylation and up-regulation of gene transcription in Schistosoma mansoni. Mol Biochem Parasitol. 2009;168:7–15. doi:10.1016/j.molbiopara.2009.06.001.
72. M.Marek, S.Kannan, A.-T.Hauser, et al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog. 2013;9:e1003645. doi:10.1371/journal.ppat.1003645.
73. T.Scior, A.Bender, G.Tresadern, et al. Recognizing pitfalls in virtual screening: a critical review. J Chem Inf Model. 2012;52:867–881. doi:10.1021/ci200321u.• A concise description of problems, shortcomings, failures, and technical traps of VS methods.
74. R.C.Braga, V.M.Alves, A.C.Silva, et al. Virtual screening strategies in medicinal chemistry: the state of the art and current challenges. Curr Top Med Chem. 2014;14:1899–1912. doi:10.2174/1568026614666140929120749.•• State-of-the-art, challenges, and perspectives of VS strategies in medicinal chemistry.
75. A.J.Williams, S.Ekins. A quality alert and call for improved curation of public chemistry databases. Drug Discov Today. 2011;16:747–750. doi:10.1016/j.drudis.2011.07.007.
76. D.Fourches, E.Muratov, A.Tropsha. Trust, but verify: on the importance of chemical structure curation in cheminformatics and QSAR modeling research. J Chem Inf Model. 2010;50:1189–1204. doi:10.1021/ci100176x.• Handbook of chemical data curation.
77. D.Fourches, E.Muratov, A.Tropsha. Curation of chemogenomics data. Nat Chem Biol. 2015;11:535. doi:10.1038/nchembio.1881.
78. J.B.Baell, G.A.Holloway. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem. 2010;53:2719–2740. doi:10.1021/jm901137j.•• Importance of PAINS in drug discovery.
79. C.-Y.Chang, M.-T.Hsu, E.X.Esposito, et al. Oversampling to overcome overfitting: exploring the relationship between data set composition, molecular descriptors, and predictive modeling methods. J Chem Inf Model. 2013;53:958–971. doi:10.1021/ci4000536.
80. A.V.Zakharov, M.L.Peach, M.Sitzmann, et al. QSAR modeling of imbalanced high-throughput screening data in PubChem. J Chem Inf Model. 2014;54:705–712. doi:10.1021/ci400737s.
81. A.C.Schierz. Virtual screening of bioassay data. J Cheminform. 2009;1:21. doi:10.1186/1758-2946-1-21.
82. N.Huang, B.K.Shoichet, J.J.Irwin. Benchmarking sets for molecular docking. J Med Chem. 2006;49:6789–6801. doi:10.1021/jm0600592.•• Overview of docking approaches.
83. T.Kalliokoski, H.S.Salo, M.Lahtela-Kakkonen, et al. The effect of ligand-based tautomer and protomer prediction on structure-based virtual screening. J Chem Inf Model. 2009;49:2742–2748. doi:10.1021/ci900364w.
84. J.-H.Lin. Accommodating protein flexibility for structure-based drug design. Curr Top Med Chem. 2011;11:171–178. doi:10.2174/156802611794863580.
85. F.R.Salsbury. Molecular dynamics simulations of protein dynamics and their relevance to drug discovery. Curr Opin Pharmacol. 2010;10:738–744. doi:10.1016/j.coph.2010.09.016.
86. D.W.Borhani, D.E.Shaw. The future of molecular dynamics simulations in drug discovery. J Comput Aided Mol Des. 2012;26:15–26. doi:10.1007/s10822-011-9517-y.
87. X.Hou, K.Li, X.Yu, et al. Protein flexibility in docking-based virtual screening: discovery of novel lymphoid-specific tyrosine phosphatase inhibitors using multiple crystal structures. J Chem Inf Model. 2015;55:1973–1983. doi:10.1021/acs.jcim.5b00344.
88. C.Liao, M.Sitzmann, A.Pugliese, et al. Software and resources for computational medicinal chemistry. Future Med Chem. 2011;3:1057–1085. doi:10.4155/fmc.11.63.
89. M.Xu, M.A.Lill. Induced fit docking, and the use of QM/MM methods in docking. Drug Discov Today Technol. 2013;10:e411–e418. doi:10.1016/j.ddtec.2013.02.003.
90. R.C.Braga, C.H.Andrade. Assessing the performance of 3D pharmacophore models in virtual screening: how good are they? Curr Top Med Chem. 2013;13:1127–1138. doi:10.2174/1568026611313090010.
91. A.Tropsha. Best practices for QSAR model development, validation, and exploitation. Mol Inform. 2010;29:476–488. doi:10.1002/minf.201000061.
92. H.van de Waterbeemd, E.Gifford. ADMET in silico modelling: towards prediction paradise? Nat Rev Drug Discov. 2003;2:192–204. doi:10.1038/nrd1032.
93. R.C.Braga, V.M.Alves, M.F.B.Silva, et al. Pred-hERG: a novel web-accessible computational tool for predicting cardiac toxicity. Mol Inform. 2015;34:698–701. doi:10.1002/minf.201500040.
94. V.M.Alves, E.Muratov, D.Fourches, et al. Predicting chemically-induced skin reactions. Part I: QSAR models of skin sensitization and their application to identify potentially hazardous compounds. Toxicol Appl Pharmacol. 2015;284:262–272. doi:10.1016/j.taap.2014.12.014.
95. H.Kubinyi. The changing landscape in drug discovery. In: Stroud RM, editor. Computational approaches to structure baseddrug design. London: Royal Society of Chemistry; 2007. p. 24–45.
96. M.N.Drwal, R.Griffith. Combination of ligand- and structure-based methods in virtual screening. Drug Discov Today Technol. 2013;10:e395–e401. doi:10.1016/j.ddtec.2013.02.002.
97. A.Lavecchia, C.Di Giovanni. Virtual screening strategies in drug discovery: a critical review. Curr Med Chem. 2013;20:2839–2860. doi:10.2174/09298673113209990001.
98. P.J.Hotez, M.E.Bottazzi, U.Strych. New vaccines for the world’s poorest people. Annu Rev Med. 2016;67:405–417. doi:10.1146/annurev-med-051214-024241.
99. E.N.Muratov, E.V.Varlamova, A.G.Artemenko, et al. Existing and developing approaches for QSAR analysis of mixtures. Mol Inform. 2012;31:202–221. doi:10.1002/minf.201100129.
100. Uniting to Combat NTDs. The London Declaration [Internet]; [cited 2016 Mar16]. Available from: http://unitingtocombatntds.org/resource/london-declaration